Atlas Trials

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

Clinical trial NCT07672769 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07672769
Sponsor
Faron Pharmaceuticals Ltd
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Higher Risk Myelodysplastic Syndromes
Start date
2026-10-01
Primary completion
2027-11-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.